StoxSai Life Sciences vs Acutaas Chemicals: share price & financials comparison
NSE: SAILIFE vs ACUTAAS · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sai Life Sciences vs Acutaas Chemicals at a glance
Sai Life Sciences (SAILIFE) has a market capitalisation of ₹40,972 Cr, against ₹33,069 Cr for Acutaas Chemicals (ACUTAAS). Over the past year Acutaas Chemicals has returned +120.2%, compared with +108.9% for Sai Life Sciences. On valuation, Acutaas Chemicals trades at a lower P/E of 75.3 versus 202.3. Acutaas Chemicals earns a higher return on equity (23.6% vs 7.5%). Sai Life Sciences comes out ahead on technicals. Acutaas Chemicals comes out ahead on size, profitability, growth and financial health. Across the scored metrics below, Sai Life Sciences leads on 3 and Acutaas Chemicals on 8. On StoxGud's 10-point checklist, Sai Life Sciences scores 6/10 and Acutaas Chemicals scores 8/10.
| Metric | Sai Life Sciences | Acutaas Chemicals |
|---|---|---|
| Size | ||
| Market cap | ₹40,972 Cr | ₹33,069 Cr |
| Revenue (latest FY) | ₹2,192 Cr | ₹1,339 Cr |
| Net profit (latest FY) | ₹349 Cr | ₹356 Cr |
| Valuation | ||
| P/E | 202.3 | 75.3 |
| P/B | 15.24 | 17.80 |
| Dividend yield | — | 0.04% |
| Profitability | ||
| Return on equity | 7.5% | 23.6% |
| Net profit margin | 8.5% | 27.6% |
| Operating margin | 29.5% | 39.1% |
| Growth | ||
| Revenue growth (YoY) | +22.5% | +42.7% |
| Net profit growth (YoY) | — | +73.3% |
| Revenue CAGR (multi-year) | — | +26.7% |
| Financial health | ||
| Debt to equity | 0.17 | 0.00 |
| Momentum | ||
| 1-month return | +31.9% | +27.1% |
| 1-year return | +108.9% | +120.2% |
| 3-year CAGR | — | +95.5% |
| 5-year CAGR | — | +52.3% |
| Distance from 52W high | +0.0% | +0.0% |
| Technicals | ||
| RSI (14) | 93 | 79 |
| Price vs 200-day avg | +56.3% | +38.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sai Life Sciences | Acutaas Chemicals |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sai Life Sciences or Acutaas Chemicals?
Sai Life Sciences has a market cap of ₹40,972 Cr and Acutaas Chemicals has a market cap of ₹33,069 Cr as of 13 Nov 2026.
Which has a lower P/E, Sai Life Sciences or Acutaas Chemicals?
Acutaas Chemicals has the lower P/E: Sai Life Sciences trades at 202.3 and Acutaas Chemicals at 75.3.
Which gave better returns in the last year, Sai Life Sciences or Acutaas Chemicals?
Acutaas Chemicals did better: Sai Life Sciences returned +108.9% and Acutaas Chemicals returned +120.2% over one year.
What is the difference between Sai Life Sciences and Acutaas Chemicals?
Both are NSE-listed companies in Healthcare. Sai Life Sciences is about 1.2 times the size of Acutaas Chemicals by market cap. In the latest financial year Sai Life Sciences reported revenue of ₹2,192 Cr and Acutaas Chemicals ₹1,339 Cr. Operating margin is 29.5% for Sai Life Sciences and 39.1% for Acutaas Chemicals. Debt to equity is 0.17 for Sai Life Sciences and 0.00 for Acutaas Chemicals.
Which is better, Sai Life Sciences or Acutaas Chemicals?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Sai Life Sciences leads on 3 and Acutaas Chemicals on 8. Sai Life Sciences is ahead on technicals. Acutaas Chemicals is ahead on size, profitability, growth and financial health. On StoxGud's rules-based checklist Sai Life Sciences scores 6/10 and Acutaas Chemicals scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.